The board of Sino Biopharmaceutical (SBMFF) announced that the Group's self-developed Recombinant Human Coagulation Factor VIIa N01 for Injection, with brand name: Anqixin - has been approved for marketing by the National Medical Products Administration of China. It is used for the treatment of bleeding in adult and adolescent patients with congenital hemophilia whose inhibitors to coagulation factor VIII or IX exceed 5 Bethesda units.
The company noted that Anqixin is currently the only recombinant human coagulation factor VIIa in China that has been confirmed for efficacy and safety through a Phase III clinical trial.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.